Two new CHEK2 germ-line variants detected in breast cancer/sarcoma families negative for BRCA1, BRCA2, and TP53 gene mutations

Breast Cancer Research and Treatment

Volumn 130, Issue 1, 2011, Pages 207-215

  Manoukian, Siranoush ^a   Peissel, Bernard ^a   Frigerio, Simona ^a   Lecis, Daniele ^a   Bartkova, Jirina ^b   Roversi, Gaia ^a   Radice, Paolo ^a,c   Bartek, Jiri ^b,d   Delia, Domenico ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^c FIRC INSTITUTE OF MOLECULAR ONCOLOGY   (Italy)

^d PALACKÝ UNIVERSITY   (Czech Republic)

Author keywords

Breast cancer; CHEK2; Hereditary predisposition; Mutation; Sarcoma

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; CHECKPOINT KINASE 2; MUTANT PROTEIN; PROTEIN P53;

ADENOSARCOMA; AMINO ACID SUBSTITUTION; ARTICLE; BRCA2 GENE; BREAST CANCER; BREAST SARCOMA; CHECKPOINT KINASE 2 GENE; CONTROLLED STUDY; CROSSOVER PROCEDURE; FAMILIAL CANCER; FAMILY HISTORY; FAMILY STUDY; GENE; GENE MUTATION; GENE SEQUENCE; GENETIC SCREENING; GENETIC VARIABILITY; GERM LINE; HUMAN; HUMAN TISSUE; INTRADUCTAL CARCINOMA; INVASIVE CARCINOMA; LOSS OF FUNCTION MUTATION; MISSENSE MUTATION; MUTATIONAL ANALYSIS; NUCLEOTIDE SEQUENCE; ONCOGENE; OSTEOSARCOMA; OVARY CANCER; PEDIGREE ANALYSIS; PHENOTYPE; PRIORITY JOURNAL; RECTUM CARCINOMA; RELATIVE; SEGREGATION ANALYSIS; SIBLING; TP53 GENE; UTERINE ADENOSARCOMA; UTERUS CANCER;

ALLELES; BREAST NEOPLASMS; CELL LINE, TUMOR; FAMILY HEALTH; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, BRCA1; GENES, BRCA2; GENES, P53; GENETIC PREDISPOSITION TO DISEASE; GERM-LINE MUTATION; HCT116 CELLS; HUMANS; MIDDLE AGED; PEDIGREE; PROTEIN-SERINE-THREONINE KINASES; SARCOMA;

EID: 82455220239     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-011-1548-5     Document Type: Article

References (32)

1. Delia, D, Buscemi G (2007) Regulation of cell cycle, cell cycle checkpoints, and cancer. In: Alison M (ed) The cancer handbook, 2nd edn. Wiley, New York, pp 36-46
2. Jackson SP, Bartek J (2009) The DNA-damage response in human biology and disease. Nature 461:1071-1078
3. Antoni L, Sodha N, Collins I et al (2007) CHK2 kinase: cancer susceptibility and cancer therapy-two sides of the same coin? Nat Rev Cancer 7:925-936 (Pubitemid 350165855)
4. Buscemi G, Carlessi L, Zannini L et al (2006) DNA damageinduced cell cycle regulation and function of novel Chk2 phosphoresidues. Mol Cell Biol 26:7832-7845 (Pubitemid 44630985)
5. Meijers-Heijboer H, van den Ouweland A, Klijn J et al (2002) Low-penetrance susceptibility to breast cancer due to CHEK2 1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet 31:55-59
6. *1100delC genotyping for clinical assessment of breast cancer risk: meta-analyses of 26, 000 patient cases and 27, 000 controls. J Clin Oncol 26:542-548 (Pubitemid 351264346)
7. Nevanlinna H, Bartek J (2006) The CHEK2 gene and inherited breast cancer susceptibility. Oncogene 25:5912-5919 (Pubitemid 44453447)
8. Caligo MA, Agata S, Aceto G et al (2004) The CHEK2 c.1100delC mutation plays an irrelevant role in breast cancer predisposition in Italy. Hum Mutat 24:100-101 (Pubitemid 38859229)
9. Narod SA (2010) Testing for CHEK2 in the cancer genetics clinic: ready for prime time? Clin Genet 72:1-7
10. Falchetti M, Lupi R, Rizzolo P et al (2008) BRCA1/BRCA2 rearrangements and CHEK2 common mutations are infrequent in Italian male breast cancer cases. Breast Cancer Res Treat 110:161-167 (Pubitemid 351793854)
11. Escudie P, Monteil-Onteniente S, Gladieff L et al (2010) A novel germline CHEK2 deletion truncating the kinase domain identified in a French family with high-risk of breast/ovarian cancer. Breast Cancer Res Treat 120:267-270
12. Dong X, Wang L, Taniguchi K et al (2003) Mutations in CHEK2 associated with prostate cancer risk. Am J Hum Genet 72:270-280 (Pubitemid 36194238)
13. Cybulski C, Górski B, Huzarski T et al (2004) CHEK2 is a multiorgan cancer susceptibility gene. Am J Hum Genet 75:1131-1135 (Pubitemid 39532081)
14. Cybulski C, Wokolorczyk D, Kladny J et al (2007) Germline CHEK2 mutations and colorectal cancer risk: different effects of a missense and truncating mutations? Eur J Hum Genet 15:237-241 (Pubitemid 46111863)
15. Gronwald J, Cybulski C, Piesiak W et al (2009) Cancer risks in first-degree relatives of CHEK2 mutation carriers: effects of mutation type and cancer site in proband. Br J Cancer 100:1508-1512
16. Robson M (2010) CHEK2, breast cancer, and the understanding of clinical utility. Clin Genet 78:8-10
17. Bell DW, Varley JM, Szydlo TE et al (1999) Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. Science 286:2528-2531
18. Sodha N, Houlston RS, Bullock S et al (2002) Increasing evidence that germline mutations in CHEK2 do not cause Li-Fraumeni syndrome. Hum Mutat 20:460-462 (Pubitemid 35453563)
19. Evans DG, Birch JM, Narod SA (2008) Is CHEK2 a cause of the Li-Fraumeni syndrome? J Med Genet 45:63-64
20. Ruijs MW, Broeks A, Menko FH et al (2009) The contribution of CHEK2 to the TP53-negative Li-Fraumeni phenotype. Hered Cancer Clin Pract 7:4
21. Manoukian S, Peissel B, Pensotti V et al (2007) Germline mutations of TP53 and BRCA2 genes in breast cancer/sarcoma families. Eur J Cancer 43:601-606 (Pubitemid 46177595)
22. Birch JM, Hartley AL, Tricker KJ et al (1994) Prevalence and diversity of constitutional mutations in the p53 gene among 21 Li-Fraumeni families. Cancer Res 54:1298-1304 (Pubitemid 24108072)
23. Sullivan A, Yuille M, Repellin C et al (2002) Concomitant inactivation of p53 and Chk2 in breast cancer. Oncogene 21:1316-1324 (Pubitemid 34214497)
24. Bartkova J, Guldberg P, Gronbaek K et al (2004) Aberrations of the Chk2 tumour suppressor in advanced urinary bladder cancer. Oncogene 23:8545-8551 (Pubitemid 39540805)
25. Lee SB, Kim SH, Bell DW et al (2001) Destabilization of CHK2 by a missense mutation associated with Li-Fraumeni Syndrome. Cancer Res 61:8062-8067 (Pubitemid 33091590)
26. Shaag A, Walsh T, Renbaum P et al (2005) Functional and genomic approaches reveal an ancient CHEK2 allele associated with breast cancer in the Ashkenazi Jewish population. Hum Mol Genet 14:555-563 (Pubitemid 40277471)
27. Sodha N, Mantoni TS, Tavtigian SV et al (2006) Rare germ line CHEK2 variants identified in breast cancer families encode proteins that show impaired activation. Cancer Res 66:8966-8970 (Pubitemid 44521112)
28. Falck J, Lukas C, Protopopova M et al (2001) Functional impact of concomitant versus alternative defects in the Chk2-p53 tumour suppressor pathway. Oncogene 20:5503-5510 (Pubitemid 32889487)
29. Jekimovs CR, Chen X, Arnold J et al (2005) Low frequency of CHEK2 1100delC allele in Australian multiple-case breast cancer families: functional analysis in heterozygous individuals. Br J Cancer 92:784-790 (Pubitemid 40460618)
30. *1100delC and other low-penetrance breast-cancer susceptibility genes: a familial study. Lancet 366:1554-1557 (Pubitemid 41540113)
31. Byrnes GB, Southey MC, Hopper JL (2008) Are the so-called low penetrance breast cancer genes, ATM, BRIP1, PALB2 and CHEK2, high risk for women with strong family histories? Breast Cancer Res 10:208
32. Houlston RS, Peto J (2004) The search for low-penetrance cancer susceptibility alleles. Oncogene 23:6471-6476 (Pubitemid 39265510)